Products & Services

VTI’s CMO Dr. Ashley Tuan on NaturalVue and the PROTECT Study

sponsored content

March 15, 2022

Visioneering Technologies Inc. (VTI) has launched an international clinical trial that will test the efficacy of its NaturalVue (etafilcon A) Multifocal 1-Day contact lenses. The study, referred to as PROTECT” (PROgressive Myopia Treatment Evaluation for NaturalVue Multifocal  Contact Lens Trial), is a multi-center, randomized, double-masked clinical trial with participating investigators in centers in Canada, the United States, and Hong Kong.

In a new video, VTI’s Chief Medical Officer, Ashley Tuan, OD, PhD, sat down with Review of Myopia Management’s Editor-in-Chief John Sailer to discuss the latest from the PROTECT study, as well as the benefits of using the NaturalVue multifocal contact lenses for myopia management. Dr. Tuan discussed how her experience in the eye care field has influenced her work at VTI, and she explained how the company plans to leverage its current data to continue to innovate in the myopia management field.

Watch the full video here:


To Top